Documente Academic
Documente Profesional
Documente Cultură
Bisphosphonate-related osteonecrosis of the jaw review the 2006 recommendations, appraise the current
(BRONJ) adversely affects the quality of life, producing published data, and revise the Position Paper and recom-
significant morbidity in afflicted patients. Strategies for mendations, where indicated. This update contains revi-
the treatment of patients with, or at risk of, BRONJ were sions to the diagnosis and staging and management strate-
set forth in the American Association of Oral and gies and highlights the status of basic science research.
Maxillofacial Surgeons (AAOMS) Position Paper on AAOMS considers it vitally important that this information
Bisphosphonate-Related Osteonecrosis of the Jaws be disseminated to other dental and medical specialties.
(Position Paper) and approved by the Board of Trust-
ees in September 2006.1 The Position Paper was Purpose
developed by a Task Force appointed by the Board The purpose of this updated position paper is to
and composed of clinicians with extensive experi- provide:
ence in caring for these patients and basic science
researchers. The knowledge base and experience in 1. Perspectives on the risk of developing BRONJ
addressing BRONJ has expanded, necessitating mod- and the risks and benefits of bisphosphonates to
ifications and refinements to the original Position facilitate medical decision-making of both the
Paper. The Task Force was reconvened in August 2008 to treating physician and the patient
*Associate Professor, Division of Oral and Maxillofacial Surgery, article; Dr Assael is a paid consultant for Novartis and has received
Stony Brook School of Dental Medicine; Attending, Long Island honoraria from Novartis and Merck; Dr Landesberg has received
Jewish Medical Center, New Hyde Park, NY; New York Center for honoraria from Novartis Pharmaceutical Corporation; Dr Marx is a
Orthognathic and Maxillofacial Surgery, Lake Success, NY. paid consultant for Medtronics and is a shareholder for Harvest
†Visiting Oral and Maxillofacial Surgeon and Director, Center for Technologies. He receives royalties from Quintessence Publishing.
Applied Clinical Investigation, Department of Oral and Maxillofa- Stryker, Synthes Maxillofacial, Biomet 3i, and Biomet Microfixation
cial Surgery, Massachusetts General Hospital; Associate Professor, provide residency support at the Miami School of Medicine, al-
Harvard School of Dental Medicine, Boston, MA. though Dr Marx receives no personal monies from this funding.
‡Professor and Chairman, Oral and Maxillofacial Surgery, Oregon Dr Marx is a voluntary unpaid expert witness for Osborn LLC
Health and Science University, Portland, OR.
attorneys in litigation against Novartis Pharmaceuticals and Merck
§Associate Professor, Division Oral Maxillofacial Surgery, Colum-
Co. Dr Mehrotra served as a consultant and on the Advisory Board
bia University School of Dental and Oral Surgery, New York, NY.
and Speaker’s Bureau for Novartis Pharmaceuticals.
¶Professor of Surgery and Chief, Division of Oral and Maxillofa-
Address correspondence and reprint requests to Dr Ruggiero:
cial Surgery, University of Miami School of Medicine, Miami, FL.
Division of Oral and Maxillofacial Surgery, Stony Brook School of
储Section Head, Division of Medical Oncology, Long Island Jewish
Dental Medicine, Long Island Jewish Medical Center, New Hyde
Medical Center, and Associate Professor of Clinical Medicine, Al-
Park, NY; New York Center for Orthognathic and Maxillofacial
bert Einstein College of Medicine, New Hyde Park, NY.
Surgery, 2001 Marcus Avenue, Lake Success, NY 11042; e-mail:
Approved by the Board of Trustees January 2009.
Dr Ruggiero is a paid consultant for Amgen Corporation and drruggiero@nycoms.com
© 2009 American Association of Oral and Maxillofacial Surgeons
Procter and Gamble and has received honorarium from Novartis;
Dr Dodson states no financial arrangements or affiliations with a 0278-2391/09/6705-0102$36.00/0
2
RUGGIERO ET AL 3
2. Guidance to clinicians regarding the differential diag- nates pamidronate (Aredia) and zoledronic acid (Zo-
nosis of BRONJ in patients with a history of treatment meta), notified healthcare professionals of additions to
with intravenous (IV) or oral bisphosphonates the labeling of these products that provided cautionary
3. Guidance to clinicians on possible BRONJ preven- language related to the development of osteonecrosis of
tion measures and treatment of patients with BRONJ the jaws.33 This was followed in 2005 by a broader drug
according to the presenting stage of the disease class warning of this complication for all bisphospho-
nates, including the oral preparations.34,35 See Appen-
Background dix 1 for a list of bisphosphonate medications currently
available in the United States.
INDICATIONS AND BENEFITS OF
BISPHOSPHONATE THERAPY
Causality
IV Bisphosphonates Epidemiologic studies have established a compel-
IV bisphosphonates are primarily used and effec- ling, albeit circumstantial, association between IV
tive in the treatment and management of cancer- bisphosphonates and BRONJ in the setting of ma-
related conditions, including hypercalcemia of malig- lignant disease. An association between IV bisphos-
nancy, skeletal-related events associated with bone phonate exposure and BRONJ can be hypothesi-
metastases in the context of solid tumors such as zed from the following observations: 1) a positive
breast cancer, prostate cancer, and lung cancer, and correlation between bisphosphonate potency and
management of lytic lesions in the setting of multiple the risk of developing BRONJ; 2) a negative corre-
myeloma.2-13 Although bisphosphonates have not lation between bisphosphonate potency and dura-
been shown to improve cancer-specific survival, they tion of bisphosphonate exposure before develop-
have had a significant positive effect on the quality of ing BRONJ; and 3) a positive correlation between
life for patients with advanced cancer involving the the duration of bisphosphonate exposure and de-
skeleton. Before 2001, pamidronate (Aredia; Novartis veloping BRONJ. However, the current level of
Pharmaceuticals, East Hanover, NJ) was the only drug evidence does not fully support a cause-and-effect
approved in the United States for the treatment of relationship between bisphosphonate exposure
metastatic bone disease. In 2002, zoledronic acid and necrosis of the jaws.36 Although causality might
(Zometa; Novartis Pharmaceuticals) was approved never be proven, emerging experimental and epi-
for this indication by the US Food and Drug Admin- demiologic studies have established a firm founda-
istration (FDA).13 More recently, a once-yearly infu- tion for a strong association between monthly IV
sion of zoledronate (Reclast; Novartis Pharmaceuti- bisphosphonate therapy and the development of
cals) and a parenteral formulation of ibandronate BRONJ. The causal association between oral or IV
(Boniva; Roche, Basel, Switzerland) administered bisphosphonates for treating osteoporosis and
every 3 months have been approved by the FDA for BRONJ is much more difficult to establish.
management of osteoporosis.14
Oral Bisphosphonates BRONJ Case Definition
Oral bisphosphonates are approved to treat osteo- To distinguish BRONJ from other delayed healing
porosis and are frequently used to treat osteopenia as conditions, the following working definition of
well.15 They are also used for a variety of less com- BRONJ has been adopted by the AAOMS and re-
mon conditions such as Paget’s disease of bone and mains unchanged from the original Position Paper:1
osteogenesis imperfecta of childhood.16,17 By far the
most prevalent and common indication, however, is Patients may be considered to have BRONJ if all of the
osteoporosis.18,19 Osteoporosis can arise in the con- following 3 characteristics are present:
text of other diseases such as inflammatory bowel
1. Current or previous treatment with a bisphosphonate
disease or primary biliary cirrhosis, as a result of
2. Exposed bone in the maxillofacial region that has
medications, most commonly steroids, or as a conse- persisted for more than 8 weeks
quence of postmenopausal aging.20-22 3. No history of radiation therapy to the jaws
Estimated Incidence and Factors greater than the risk of BRONJ for patients receiving
Associated With Development oral bisphosphonates. Regardless, given the large
of BRONJ number of patients receiving oral bisphosphonates
for the treatment of osteoporosis/osteopenia, it is
IV BISPHOSPHONATES AND INCIDENCE OF BRONJ
likely that most practitioners will encounter some
The clinical efficacy of IV bisphosphonates for the patients with BRONJ. It is important to accurately
treatment of hypercalcemia and bone metastases is determine the incidence of BRONJ in this population
well established.2-5 IV bisphosphonate exposure in and to assess the risk associated with long-term use
the setting of managing malignancy remains the major (ie, longer than 3 years) of oral bisphosphonates. The
risk factor for BRONJ. According to case series, case- low prevalence of BRONJ in osteoporosis patients
controlled studies, and cohort studies, estimates of poses a significant challenge for future clinical trials
the cumulative incidence of BRONJ have ranged from aimed at establishing accurate incidence data.
0.8% to 12%.37-45
Zoledronic acid (Reclast) administered once annually RISK FACTORS
for the treatment of osteoporosis was approved by the In the original Position Paper, BRONJ risks were
FDA in August 2007.14 A single, large, prospective pla- categorized as drug-related, local, and demographic or
cebo-controlled study established its efficacy for this systemic factors.1 Other medications, such as steroids
indication through 3 years of treatment.46 Two cases of and thalidomide, and other chemotherapeutic agents
osteonecrosis of the jaw were reported, one each in the were thought to be risk factors, but no measurable
treatment and control groups, suggesting a low risk of associations were identified. Subsequently, 2 new sets of
BRONJ with this treatment modality through 3 years. factors, genetic and preventative, are available to report.
surgery.45,52 In the setting of IV bisphospho- peutic agents and BRONJ risk.37,39,52,53,58 Wessel
nate exposure, 4 studies reported that dentoal- et al53 reported an increased risk of BRONJ among
veolar procedures or concomitant dental dis- tobacco users, but no increased risk was associated
ease increased the risk of BRONJ between 5.3 with alcohol exposure.
(odds ratio) and 21 (relative risk).37,52,54,55
Thus, cancer patients treated with IV bisphos- IV. Genetic factors
phonates who undergo dentoalveolar proce- Sarasquete et al60 demonstrated that genetic pertur-
dures have a 5- to 21-fold increased risk of bations (ie, single nucleotide polymorphisms, in
BRONJ compared with cancer patients the cytochrome P450-2C gene [CYP2C8]) were
treated with IV bisphosphonates who do associated with an increased risk of BRONJ
not undergo dentoalveolar procedures. among multiple myeloma patients treated with
B. Local anatomy IV bisphosphonates.
1. Mandible
a. Lingual tori V. Preventive factors
b. Mylohyoid ridge The AAOMS Taskforce on BRONJ recommended
2. Maxilla that patients undergo dental evaluations and re-
a. Palatal tori ceive necessary treatment before initiating IV
It has been observed that lesions are bisphosphonate therapy.1 In addition, given the
found more commonly in the mandible long-term biologic activity of IV bisphospho-
than the maxilla (2:1 ratio) and more com- nates, one could hypothesize that different dos-
monly in areas with thin mucosa overly- ing regimens might be equally effective and de-
ing bony prominences such as tori, bony crease the risk of BRONJ.
exostoses, and the mylohyoid Using a retrospective cohort study design, Corso
ridge.24,26,56 No data are available to pro- et al58 evaluated the BRONJ- and skeletal-related
vide risk estimates for anatomic structures events (eg, pathologic fracture) in multiple my-
and BRONJ. eloma patients using different dosing schedules
C. Concomitant oral disease: cancer patients ex- for zoledronate. These findings suggest that alter-
posed to IV bisphosphonates with a history of native dosing schedules that reduce IV bisphos-
inflammatory dental disease (eg, periodontal phonate exposure have comparable outcomes in
and dental abscesses) are at a 7-fold increased terms of preventing skeletal-related events and a
risk of developing BRONJ.45 decreased risk of BRONJ.
Since the original Position Paper on BRONJ, sev-
III. Demographic and systemic factors eral studies have generated quantitative esti-
In the original Position Paper, age, race, and can- mates of risk of BRONJ in the setting of IV
cer diagnosis with or without osteoporosis were bisphosphonates exposure. The 2 largest risk fac-
reported as risk factors for BRONJ.1 Seven stud- tors for BRONJ are IV bisphosphonate exposure
ies reported increasing age as consistently asso- and dentoalveolar procedures. Recent studies
ciated with BRONJ.38,39,52,54,55,57,58 Sex was not have suggested that manipulation of IV bisphos-
significantly associated statistically with phonate dosing might be effective in reducing
BRONJ.38,39,52,54,55,57 Race was reported in 1 skeletal-related events and minimizing BRONJ
study to be a risk factor, with whites having an risk.58 In addition, preventive dental interven-
increased risk of BRONJ compared with blacks.52 tions before initiating IV bisphosphonate treat-
Other systemic factors or conditions (ie, renal dial- ment can also effectively reduce, but not elimi-
ysis, low hemoglobin, obesity, and diabetes) nate, the risk of BRONJ.
were variably reported to increase the risk of
BRONJ.53,54,59 Malignancy type was not signifi- Management Strategies for Patients
cantly associated statistically with an increased Treated With Bisphosphonates
risk of BRONJ,38 although the presence of meta-
static disease reached near statistical significance PREVENTION OF BRONJ
(P ⫽ .051) in the report by Wessel et al.53 Before treatment with monthly IV bisphosphonates, the
In contrast to the original Position Paper, a few patient should undergo a thorough oral examination, any
current studies have noted an increased risk of unsalvageable teeth should be removed, all invasive dental
BRONJ among patients exposed to chemothera- procedures should be completed, and optimal periodontal
peutic agents (ie, cyclophosphamide, erythropoie- health should be achieved.
tin, and steroids).54,57 Others, however, have failed Three studies have reported that preventive dental
to confirm the association between chemothera- treatment decreased the BRONJ risk among patients
6 AAOMS POSITION PAPER—2009 UPDATE
with malignancy treated with IV bisphosphonates.61-63 ously, most affected patients experience this compli-
These findings suggest that, although BRONJ is not elim- cation after dentoalveolar surgery.37,45,52 Therefore, if
inated, dental evaluations and treatment before initiating systemic conditions permit, initiation of bisphospho-
IV bisphosphonate therapy among cancer patients re- nate therapy should be delayed until the dental health
duces the BRONJ risk. has been optimized.61-63 This decision must be made in
The risk of developing BRONJ associated with oral conjunction with the treating physician and dentist and
bisphosphonates, although exceedingly small, ap- other specialists involved in the care of the patient.
pears to increase when the duration of therapy ex- Nonrestorable teeth and teeth with a poor progno-
ceeds 3 years. This period can be shortened in the sis should be extracted. Other necessary elective den-
presence of certain comorbidities, such as chronic cor- toalveolar surgery should also be completed at this
ticosteroid use. If systemic conditions permit, the clini- time. From the experience with osteoradionecrosis,
cian might consider discontinuation of oral bisphospho- it appears advisable that bisphosphonate therapy
nates for a 3-month period before and 3-month period should be delayed, if systemic conditions permit,
after elective invasive dental surgery to lower the risk of until the extraction site has mucosalized (14 to 21
BRONJ. The rationale for this approach is based on days) or until adequate osseous healing has occurred.
extrapolated data demonstrating fluctuations in oste- Dental prophylaxis, caries control, and conservative
oclast function related to bisphosphonate therapy and restorative dentistry are critical to maintaining func-
recent outcomes studies that have shown improved tionally sound teeth. This level of care must be con-
outcomes of BRONJ treatment with drug cessation.61-64 tinued indefinitely.
Long-term, prospective studies are required to establish Patients with full or partial dentures should be
the efficacy of drug “holidays” in reducing the risk of examined for areas of mucosal trauma, especially
BRONJ for patients receiving oral bisphosphonates. The along the lingual flange region. It is critical that pa-
risk reduction could vary depending on the duration of tients be educated as to the importance of dental
bisphosphonate exposure. Modification or cessation of hygiene and regular dental evaluations and specifi-
oral bisphosphonate therapy should be done in consul- cally instructed to report any pain, swelling, or ex-
tation with the treating physician and the patient. posed bone.
Medical oncologists should evaluate and treat pa-
TREATMENT GOALS tients scheduled to receive IV bisphosphonates simi-
The major goals of treatment for patients at risk of larly to those patients scheduled to initiate radiother-
developing or who have BRONJ are: apy to the head and neck. The osteoradionecrosis
prevention protocols are guidelines that are familiar
Prioritization and support of continued oncologic to most oncologists and general dentists.
treatment in patients receiving IV bisphosphonates.
Oncology patients can benefit greatly from the thera- Asymptomatic Patients Receiving
peutic effect of bisphosphonates by controlling IV Bisphosphonates
bone pain and reducing the incidence of other Maintaining good oral hygiene and dental care is of
skeletal complications. paramount importance in preventing dental disease
that might require dentoalveolar surgery. Procedures
Preservation of quality of life through: that involve direct osseous injury should be avoided.
Nonrestorable teeth can be treated by removal of the
Patient education and reassurance crown and endodontic treatment of the remaining
Control of pain roots.67 Placement of dental implants should be
Control of secondary infection avoided in the oncology patient exposed to the more
Prevention of extension of lesion and development of potent IV bisphosphonate medications (zoledronic
new areas of necrosis acid and pamidronate) on a frequent dosing schedule
(4 to 12 times annually).
TREATMENT STRATEGIES Zoledronic acid (Reclast) administered once annually
The treatment strategies have been determined for the treatment of osteoporosis was approved by the
from published studies.26,31,65-67 FDA in August 2007.14 A single, large, prospective pla-
cebo-controlled study established its efficacy for this
Patients About to Initiate IV indication through 3 years of treatment.46 Two cases of
Bisphosphonate Treatment osteonecrosis of the jaw were reported, one each in the
The treatment objective for this group of patients is treatment and control groups, suggesting a low risk of
to minimize the risk of developing BRONJ. Although a BRONJ with this treatment modality through 3 years.
small percentage of patients receiving bisphospho- The efficacy of a drug holiday for patients receiving
nates develop osteonecrosis of the jaw spontane- yearly zoledronic acid therapy and the appropriate tim-
RUGGIERO ET AL 7
ing of dentoalveolar surgery (if required) is unknown over to assess the risk of developing jaw necrosis in
and requires additional study. patients at risk requires additional research before it can
be considered a valid risk assessment tool. Long-term,
Asymptomatic Patients Receiving Oral
Bisphosphonate Therapy prospective studies are also required to establish the
Patients receiving oral bisphosphonates are also at efficacy of drug holidays in reducing the risk of BRONJ
risk of developing BRONJ but to a much lesser degree for these patients.
than those treated with IV bisphosphonates.24,26,27,56 The risk of BRONJ might be associated with an
BRONJ can develop spontaneously or after minor increased duration of treatment with oral bisphos-
trauma. In general, these patients seem to have less phonates (ie, 3 or more years). No information is
severe manifestations of necrosis and respond more available to suggest that monthly dosing of oral
readily to stage-specific treatment regimens68,69 (Table bisphosphonates (ie, ibandronate [Boniva], risedr-
1). Elective dentoalveolar surgery does not appear to be onate [Actonel]) is associated with either an ele-
contraindicated in this group. It is recommended that vated or reduced risk of BRONJ compared with
patients be adequately informed of the small risk of weekly dosing regimens. The risk of long-term oral
compromised bone healing. The use of bone turnover bisphosphonate therapy clearly requires continued
marker levels, in conjunction with a drug holiday, has analysis and research.
been reported as an additional tool to guide treatment Sound recommendations determined from strong
decisions in patients exposed to oral bisphosphonates.68 clinical research designs are still lacking for patients
The efficacy of using a systemic marker of bone turn- taking oral bisphosphonates. The Task Force strate-
At risk category No apparent necrotic bone in patients who have been No treatment indicated
treated with either oral or IV bisphosphonates Patient education
Stage 0 No clinical evidence of necrotic bone, but nonspecific Systemic management, including use of
clinical findings and symptoms pain medication and antibiotics
Stage 1 Exposed and necrotic bone in asymptomatic patients Antibacterial mouth rinse
without evidence of infection Clinical follow-up on quarterly basis
Patient education and review of indications
for continued bisphosphonate therapy
Stage 2 Exposed and necrotic bone associated with infection as Symptomatic treatment with oral antibiotics
evidenced by pain and erythema in region of exposed Oral antibacterial mouth rinse
bone with or without purulent drainage Pain control
Superficial debridement to relieve soft
tissue irritation
Stage 3 Exposed and necrotic bone in patients with pain, infection, Antibacterial mouth rinse
and one or more of the following: exposed and necrotic Antibiotic therapy and pain control
bone extending beyond the region of alveolar bone, (ie, Surgical debridement/resection for longer
inferior border and ramus in the mandible, maxillary term palliation of infection and pain
sinus and zygoma in the maxilla) resulting in pathologic
fracture, extraoral fistula, oral antral/oral nasal
communication, or osteolysis extending to the inferior
border of the mandible or the sinus floor
Abbreviations: BRONJ, bisphosphonate-related osteonecrosis of the jaw; IV, intravenous.
*Exposed bone in maxillofacial region without resolution within 8-12 weeks in persons treated with bisphosphonate who
have not undergone radiotherapy to jaws.
†Regardless of disease stage, mobile segments of bony sequestrum should be removed without exposing uninvolved bone;
extraction of symptomatic teeth within exposed, necrotic bone should be considered because it is unlikely that extraction will
exacerbate established necrotic process.
‡Discontinuation of IV bisphosphonates has shown no short-term benefit. However, if systemic conditions permit,
long-term discontinuation might be beneficial in stabilizing established sites of BRONJ, reducing risk of new site development,
and reducing clinical symptoms. Risks and benefits of continuing bisphosphonate therapy should be made only by treating
oncologist in consultation with oral and maxillofacial surgeon and patient.
§Discontinuation of oral bisphosphonate therapy in patients with BRONJ has been associated with gradual improvement in
clinical disease. Discontinuation of oral bisphosphonates for 6-12 months may result in either spontaneous sequestration or
resolution after debridement surgery. If systemic conditions permit, modification or cessation of oral bisphosphonate therapy
should be done in consultation with treating physician and patient.
Ruggiero et al. AAOMS Position Paper—2009 Update. J Oral Maxillofac Surg 2009.
8 AAOMS POSITION PAPER—2009 UPDATE
gies outlined below have remained essentially un- strategies have been determined from the opinion of
changed from those in the original Position Paper experts and observational studies.68
and are based on clinical experience of clinicians
(expert opinion) involved in caring for these patients Patients With BRONJ
and from case series.63,65-68 The risk of developing The treatment objectives for patients with an estab-
BRONJ associated with oral bisphosphonates in- lished diagnosis of BRONJ are to eliminate pain, con-
creased when the duration of therapy exceeded 3 trol infection of the soft and hard tissue, and minimize
years. Although the current level of evidence is not the progression or occurrence of bone necrosis.
strong, the Task Force considers these strategies for These patients respond less predictably to the es-
patients receiving oral bisphosphonates as a prudent tablished surgical treatment algorithms for osteomy-
set of guidelines that will not compromise the long- elitis or osteoradionecrosis. Surgical debridement has
term management of their osteoporosis. As more data been variably effective in eradicating the necrotic
become available and a better level of evidence is bone.22-24,29 It could be difficult to obtain a surgical
obtained, these strategies will be updated and modi- margin with viable bleeding bone, because the entire
fied as necessary. jawbone has been exposed to the pharmacologic in-
For individuals who have taken an oral bisphos- fluence of the bisphosphonate. Therefore, surgical
phonate for fewer than 3 years and have no clinical treatment should be delayed if possible and reserved
risk factors, no alteration or delay in the planned for those patients with stage 3 disease or in those
surgery is necessary. This includes any and all proce- cases with well-defined sequestrum. Areas of necrotic
dures common to oral and maxillofacial surgeons, bone that are a constant source of soft-tissue irritation
periodontitis, and other dental providers. should be removed or recontoured without exposure
It is suggested that if dental implants are placed, of additional bone. Loose segments of bony seques-
informed consent should be provided related to trum should be removed without exposing unin-
possible future implant failure and possible osteo- volved bone.70 The extraction of symptomatic teeth
necrosis of the jaws if the patient continues to take within exposed, necrotic bone should be considered,
an oral bisphosphonate. Such patients should be placed because it appears unlikely that the extraction will
on a regular recall schedule. It is also advisable to exacerbate the established necrotic process.
contact the provider who originally prescribed the Patients with established BRONJ should avoid elec-
oral bisphosphonate and suggest monitoring such pa- tive dentoalveolar surgical procedures, because these
tients and considering either alternate dosing of the surgical sites could result in additional areas of ex-
bisphosphonate, drug holidays, or an alternative to
posed necrotic bone. Symptomatic patients with
the bisphosphonate therapy.
stage 3 disease might require resection and immediate
For those patients who have taken an oral
reconstruction with a reconstruction plate or an ob-
bisphosphonate for fewer than 3 years and have
turator. Recent case series have described acceptable
also taken corticosteroids concomitantly, the pre-
outcomes after surgical therapy for patients with
scribing provider should be contacted to consider
stage 2 and stage 3 disease.69 The potential for failure
discontinuation of the oral bisphosphonate (drug hol-
of the reconstruction plate because of the generalized
iday) for at least 3 months before oral surgery, if
systemic conditions permit. The bisphosphonate effects of the bisphosphonate exposure needs to be
should not be restarted until osseous healing has oc- recognized by the clinician and patient. Immediate
curred. These strategies have been determined from reconstruction with nonvascularized or vascularized
the opinion of experts with significant clinical expe- bone is still considered potentially problematic, be-
rience and the hypothesis that concomitant treatment cause necrotic bone could be present at the resection
with corticosteroids might increase the risk of devel- margins or develop at the recipient site.
oping BRONJ and that a drug holiday may mitigate The effectiveness of hyperbaric oxygen therapy as
this risk. Long-term, prospective studies are required an adjunct to nonoperative and operative treatment is
to establish the efficacy of drug holidays in reducing under investigation at 2 institutions, where a random-
the risk of BRONJ for these patients. ized controlled trial is underway.71 The preliminary
For those patients who have taken an oral results have shown some improvement in wound
bisphosphonate for more than 3 years with or with- healing and long-term pain scores, but its use as the
out any concomitant prednisone or other steroid sole treatment modality for BRONJ cannot be sup-
medication, the prescribing provider should be con- ported at this time.
tacted to consider discontinuation of the oral bisphos- Case reports with small sample sizes have docu-
phonate for 3 months before oral surgery, if systemic mented the use of other nonoperative treatment strat-
conditions permit. The bisphosphonate should not egies, including platelet-rich plasma, parathyroid hor-
be restarted until osseous healing has occurred. These mone, and bone morphogenic protein.72 The efficacy
RUGGIERO ET AL 9
of these treatment modalities needs to be established Stage 1: exposed and necrotic bone in patients who
through additional research and controlled studies. are asymptomatic and have no evidence of infection.
Stage 2: exposed and necrotic bone in patients with
Staging and Treatment Strategies pain and clinical evidence of infection.
Stage 3: exposed and necrotic bone in patients with
STAGING pain, infection, and one or more of the following:
Since the publication of the original Position Paper, Exposed necrotic bone extending beyond the re-
changes in the staging system have become necessary so gion of alveolar bone (ie, inferior border and
that patients could be more accurately stratified (Table ramus in the mandible, maxillary sinus and zy-
1). Specifically, a stage 0 category was added to include goma in the maxilla)
patients with nonspecific symptoms or clinical and ra- Pathologic fracture
diographic abnormalities that might have been due to Extraoral fistula
bisphosphonate exposure. The risk of a patient with Oral antral/oral nasal communication
stage 0 disease advancing to a higher disease stage is Osteolysis extending to the inferior border of the
unknown at this time. The definition of stage 3 disease mandible or sinus floor
was also amended to include, and more appropriately
categorize, advanced maxillary disease. TREATMENT STRATEGIES
To direct rational treatment guidelines and collect
data to assess the prognosis in patients who have used At risk: patients who are at risk of developing BRONJ
either IV or oral bisphosphonates, the AAOMS pro- because they have been exposed to a bisphospho-
poses the use of the following revised staging system. nate do not require any treatment. However, these
patients should be informed of the risks of devel-
Patients at risk: no apparent necrotic bone in asymp- oping BRONJ, as well as the signs and symptoms of
tomatic patients who have been treated with IV or this disease process.
oral bisphosphonates. Stage 0: provide symptomatic treatment, and conserva-
Stage 0: Patients with no clinical evidence of necrotic tively manage other local factors, such as caries and
bone, but who present with nonspecific symptoms periodontal disease. Systemic management can in-
or clinical and radiographic findings, including clude the use of medication for chronic pain and the
Symptoms control of infection with antibiotics, when indicated.
Odontalgia not explained by an odontogenic Stage 1: these patients benefit from the use of oral
cause antimicrobial rinses, such as chlorhexidine 0.12%.
Dull, aching bone pain in the body of the man- No surgical treatment is indicated.
dible that may radiate to the temporomandib- Stage 2: these patients benefit from the use of oral
ular joint region antimicrobial rinses combined with antibiotic ther-
Sinus pain, which could be associated with in- apy. It has been hypothesized that the pathogenesis
flammation and thickening of the maxillary of BRONJ might be related to factors adversely
sinus wall influencing bone remodeling. Additionally, BRONJ
Altered neurosensory function is not due to a primary infectious etiology. Most of
Clinical findings the isolated microbes have been sensitive to the
Loosening of teeth not explained by chronic peri- penicillin group of antibiotics. Quinolones, metro-
odontal disease nidazole, clindamycin, doxycycline, and erythromy-
Periapical/periodontal fistula that is not associ- cin have been used with success in those patients
ated with pulpal necrosis due to caries allergic to penicillin. Microbial cultures should also be
Radiographic findings analyzed for the presence of Actinomyces species of
Alveolar bone loss or resorption not attributable to bacteria. If this microbe is isolated, the antibiotic
chronic periodontal disease changes to trabecu- regimen should be adjusted accordingly. In some re-
lar pattern— dense woven bone and persistence fractory cases, patients might require combination
of unremodeled bone in extraction sockets antibiotic therapy, long-term antibiotic maintenance,
Thickening/obscuring of periodontal ligament or a course of IV antibiotic therapy.
(thickening of the lamina dura and decreased Stage 3: these patients benefit from debridement, in-
size of the periodontal ligament space) cluding resection, combined with antibiotic ther-
Inferior alveolar canal narrowing apy, which might offer long-term palliation, with
These nonspecific findings, which characterize resolution of acute infection and pain.
stage 0, can occur in patients with a history of
stage 1, 2, or 3 disease who have healed and have Regardless of the disease stage, mobile segments of
no clinical evidence of exposed bone. bony sequestrum should be removed without expos-
10 AAOMS POSITION PAPER—2009 UPDATE
and bone health issues in women with breast cancer. J Clin 28. Purcell PM, Boyd IW: Bisphosphonates and osteonecrosis of
Oncol 21:4042, 2003 the jaw. Med J Aust 182:417, 2005
7. Saad F, Gleason DM, Murray R, et al: A randomized, placebo- 29. Bagan JV, Jimenez Y, Murillo J, et al: Jaw osteonecrosis associ-
controlled trial of zoledronic acid in patients with hormone- ated with bisphosphonates: Multiple exposed areas and its
refractory metastatic prostate carcinoma. J Natl Cancer Inst relationship to teeth extractions—Study of 20 cases [Letter].
94:1458, 2002 Oral Oncol 42:327, 2006
8. Saad F, Gleason DM, Murray R, et al: Long-term efficacy of 30. Pires FR, Miranda A, Cardoso ES, et al: Oral avascular bone
zoledronic acid for the prevention of skeletal complications in necrosis associated with chemotherapy and bisphosphonate
patients with metastatic hormone-refractory prostate cancer. therapy. Oral Dis 11:365, 2005
J Natl Cancer Inst 96:879, 2004 31. Woo SB, Hellstein JW, Kalmar JR: Systematic review: Bisphos-
9. Rosen LS, Gordon D, Tchekmedyian NS, et al: Long-term effi- phonates and osteonecrosis of the jaws. Ann Intern Med 144:
cacy and safety of zoledronic acid in the treatment of skeletal 753, 2006
metastases in patients with non-small cell lung carcinoma and 32. Woo SB, Hande K, Richardson PG: Osteonecrosis of the jaws
other solid tumors: A randomized, Phase III, double-blind pla- and bisphosphonates [Letter]. N Engl J Med 353:100, 2005
cebo-controlled trial. Cancer 100:2613, 2004 33. Hohnecker JA: Novartis “Dear Doctor” precautions added to
10. Berenson JR, Lichtenstein A, Porter L, et al, for the Myeloma label of Aredia and Zometa. September 24, 2004
Aredia Study Group. Efficacy of pamidronate in reducing skel- 34. U.S. Food and Drug Administration Oncologic Drugs Advisory
etal events in patients with advanced multiple myeloma. N Engl Committee: Combidex briefing information. Available at:
J Med 334:488, 1996 http://www.fda.gov/ohms/dockets/ac/05/briefing/2005-4095b1.
11. Berenson JR, Lichtenstein A, Porter L, et al, for the Myeloma htm Accessed August 14, 2006
Aredia Study Group. Long-term pamidronate treatment of ad- 35. U.S. Food and Drug Administration, Office of Drug Safety:
vanced multiple myeloma patients reduces skeletal events. Postmarketing safety review. Available at: www.fda.gov/
J Clin Oncol 16:593, 1998 ohrms/dockets/ac/05/briefing/2005-4095B2_03_04-FDA-TAB3.
12. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pdf - 03-02-2005 -. Accessed August 14, 2006
pamidronate in the treatment of skeletal metastases in patients 36. Dodson TB: Intravenous bisphosphonate therapy and bisphos-
with breast cancer or osteolytic lesions of multiple myeloma: A phonate-related osteonecrosis of the jaws. J Oral Maxillofac
phase III double-blind, comparative trial. Cancer J 7:377, 2002 Surg 67:44, 2009 (suppl 1)
13. Berenson JR, Hillner BE, Kyle RA, et al: American Society of 37. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaws and
Clinical Oncology clinical practice guidelines: The role of bisphos- bisphosphonates [Letter]. N Engl J Med 353:99, 2005
phonates in multiple myeloma. J Clin Oncol 20:3719, 2002 38. Bamias A, Kastritis E, Bamia C, et al: Osteonecrosis of the jaw
14. United States Food and Drug Administration. Center for Drug in cancer after treatment with bisphosphonates: Incidence and
Evaluation and Research: Reclast label information. Available risk factors. J Clin Oncol 23:8580, 2005
at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. 39. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al: Osteo-
cfm?fuseaction⫽Search.Label_ApprovalHistory. Accessed March necrosis of the jaw in patients with multiple myeloma treated
13, 2009 with bisphosphonates: Evidence of increased risk after treat-
15. Physicians’ Desk Reference (ed 57). Montvale, NJ, Medical ment with zoledronic acid. Haematologica 91:968, 2006
Economics, 2003 40. Dimopoulos M, Kastritis E, Moulopoulos LA, et al: The inci-
16. Delmas PD, Meunier PJ: The management of Paget’s disease of dence of osteonecrosis of the jaw in patients with multiple
bone. N Engl J Med 336:558, 1997 myeloma who receive bisphosphonates depends on the type of
17. Letocha AD, Cintas HL, Troendle JF, et al: Controlled trial of bisphosphonate. American Society of Hematology Annual
pamidronate in children with types III and IV osteogenesis Meeting Abstracts. Blood 106:637, 2005
imperfecta confirms vertebral gains but not short-term func- 41. Tosi P, Zamagni E, Cangini D, et al: Bisphosphonates and
tional improvement. J Bone Miner Res 20:977, 2005 osteonecrosis of the jaws: Incidence in a homogeneous series
18. Watts NB. Bisphosphonate treatment of osteoporosis. Clin of patients with newly diagnosed multiple myeloma treated
Geriatr Med 19:395, 2003 with zoledronic acid. American Society of Hematology Annual
19. Delmas PD. The use of bisphosphonates in the treatment of Meeting Abstracts. Blood 106:3461, 2005
osteoporosis. Curr Opin Rheumatol 17:462, 2005 42. Pozzi S, Marcheselli R, Sacchi S, et al: Analysis of frequency and
20. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate risk factors for developing bisphosphonate associated necrosis
increases lumbar spine bone mineral density in patients with of the jaw. American Society of Hematology Annual Meeting
Crohn’s disease. Gastroenterology 119:639, 2000 Abstracts. Blood 106:5057, 2005
21. Zein CO, Jorgensen RA, Clarke B, et al: Alendronate improves 43. Cafro AM, Barbarano LA, Andriani A, et al: Osteonecrosis of the
bone mineral density in primary biliary cirrhosis: A randomized jaw associated with chronic bisphosphonates therapy: An Ital-
placebo-controlled trial. Hepatology 42:762, 2005 ian experience. American Society of Hematology Annual Meet-
22. Bone HG, Hosking D, Devogelaer JP, et al: Ten years’ experi- ing Abstracts. Blood 106:5152, 2005
ence with alendronate for osteoporosis in postmenopausal 44. Zavras AI, Zhu S: Bisphosphonate are associated with increased
women. N Engl J Med 350:1189, 2004 risk for jaw surgery in medical claims data: Is it osteonecrosis?
23. Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) in- J Oral Maxillofac Surg 64:917, 2006
duced avascular necrosis of the jaws: A growing epidemic 45. Hoff AO, Toth BB, Altundag K, et al: Osteonecrosis of the jaw in
[Letter]. J Oral Maxillofac Surg 61:1115, 2003 patients receiving intravenous bisphosphonate therapy. ASCO
24. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff S: Osteonecro- Annual Meeting Proceedings (postmeeting edition). J Clin Oncol
sis of the jaws associated with the use of bisphosphonates: A 24:8528, 2006. Available from: http://meeting.jco.org/cgi/content/
review of 63 cases. J Oral Maxillofac Surg 62:527, 2004 abstract/24/18_suppl/8528. Accessed August 14, 2006
25. Estilo CL, Van Posnak CH, Williams T, et al: Osteonecrosis of 46. Black DM, Delmas PD, Eastell R, et al, for the HORIZON Pivotal
the maxilla and mandible in patients treated with bisphospho- Fracture Trial. Once-yearly zoledronic acid for treatment of
nates: A retrospective study. J Clin Oncol 22:8088, 2004 postmenopausal osteoporosis. N Engl J Med 356:1809, 2007
26. Marx RE, Sawatari Y, Fortin M, Broumand V: Bisphosphonate- 47. IMS Health, NPA Plus: Prescription drug information. Avail-
induced exposed bone (osteonecrosis\osteopetrosis) of the able at: http://www1.imshealth.com/ims/portal/front/articleC/
jaws: risk factors, recognition, prevention and treatment. J Oral 0,2777,6599_40868211_40868264,00.html. Accessed May 2006
Maxillofac Surg 63:1567, 2005 48. Report of the Council of Scientific Affairs. Expert panel recom-
27. Migliorati CA, Schubert MM, Peterson DE, Seneda LM: Bisphos- mendations: Dental management of patients on oral bisphospho-
phonate-associated osteonecrosis of mandibular and maxillary nate therapy. American Dental Association. June 2006. Available
bone: An emerging oral complication of supportive cancer at: http://www.ada.org/prof/resources/topics/osteonecrosis.asp.
therapy. Cancer 104:83, 2005 Accessed June 29, 2006
12 AAOMS POSITION PAPER—2009 UPDATE
49. Mavrokokki T, Cheng A, Stein B, Goss A: Nature and frequency 62. Ripamonti CI, Maniezzo M, Campa T, et al: Decreased occur-
of bisphosphonate-associated osteonecrosis of the jaws in Aus- rence of osteonecrosis of the jaw after implementation of
tralia. J Oral Maxillofac Surg 65:415, 2007 dental preventive measures in solid tumour patients with bone
50. Ault A: Jaw necrosis affects 1 in 1,700 on oral bisphosphonates. metastases treated with bisphosphonates: The experience of
Internal Medicine News 41:23, August 1, 2008 the National Cancer Institute of Milan. Ann Oncol 20:137, 2009
51. Felsenberg D, Hoffmeister B: Necrosis of the jaw after high-dose 63. Mehrotra B, Fantasia J, Ruggiero SL: Outcomes of bisphospho-
bisphosphonate therapy. Deatsches Arzteblatt 103:3078, 2006 nate related osteonecrosis of the jaw. Importance of staging
52. Badros A, Weikel D, Salama A, et al: Osteonecrosis of the jaw in and management: A large single institution update. J Clin Oncol
multiple myeloma patients: Clinical features and risk factors. ASCO Meeting Abstracts 26:20526, 2008 (suppl)
J Clin Oncol 24:945, 2006 64. Rosen HN, Moses AC, Garber J, et al: Serum CTX: A new
53. Wessel JH, Dodson TB, Zavras AI: Zoledronate, smoking, and marker of bone resorption that shows treatment effect more
obesity are strong risk factors for osteonecrosis of the jaw: A often than other markers because of a low coefficient of vari-
case-control study. J Oral Maxillofac Surg 66:625, 2008 ability and large changes with bisphosphonate therapy. Calcif
54. Jadu F, Lee L, Pharoah M, Reece D, Wang L: A retrospective Tissue Int 66:100, 2000
study assessing the incidence, risk factors and comorbidities of 65. Ruggiero SL, Gralow J, Marx RE, et al: Practical guidelines for
pamidronate-related necrosis of the jaws in multiple myeloma the prevention, diagnosis and treatment of osteonecrosis of the
patients. Ann Oncol 18:2015, 2007 jaw in patients with cancer. J Clin Oncol Prac 2:7, 2006
55. Hoff AO, Toth BB, Altundag K, et al: Frequency and risk factors 66. Migliorati CA, Casiglia J, Epstein J, et al: Managing the care of
associated with osteonecrosis of the jaw in cancer patients patients with bisphosphonate-associated osteonecrosis. J Am
Dent Assoc 136:1658, 2005
treated with intravenous bisphosphonates. J Bone Miner Res
67. American Association of Endodontists Position Statement: End-
23:826, 2008
odontic implications of bisphosphonate-associated osteonecro-
56. Ruggiero SL, Fantasia J, Carlson E: Bisphosphonate-related os-
sis of the jaws. Available at: http://www.aae.org/dentalpro/
teonecrosis of the jaw: background and guidelines for diagno-
guidelines.htm. Accessed August 14, 2006
sis, staging and management. Oral Surg Oral Med Oral Path
68. Marx RE, Cillo JE, Ulloa JJ: Oral bisphosphonates induced
Oral Radiol Endod 102:433, 2006 osteonecrosis: Risk factors, prediction of risk using serum CTX
57. Zervas K, Verrou E, Teleioudis Z, et al: Incidence, risk factors testing, prevention, and treatment. J Oral Maxillofac Surg 65:
and management of osteonecrosis of the jaw in patients with 2397, 2007
multiple myeloma: A single-centre experience in 303 patients. 69. Carlson ER: The role of surgical resection in the management
Br J Haematol 134:620, 2006 of bisphosphonate-related osteonecrosis of the jaws. J Oral
58. Corso A, Varettoni M, Zappasodi P, et al: A different schedule of Maxillofac Surg 67:85, 2009 (suppl 1)
zoledronic acid can reduce the risk of the osteonecrosis of the jaw 70. Kademani D, Koka S, Lacy MQ, Rajkumar V: Primary surgical
in patients with multiple myeloma. Leukemia 21:1545, 2007 therapy for osteonecrosis of the jaw secondary to bisphospho-
59. Khamaisi M, Regev E, Yarom N, et al: Possible association nate therapy. Mayo Clin Proc 81:1100, 2006
between diabetes and bisphosphonate-related jaw osteonecro- 71. Freiberger JJ: The utility of hyperbaric oxygen in the treatment
sis. J Clin Endocrinol Metab 92:1172, 2007 of bisphosphonate-related osteonecrosis of the jaws. J Oral
60. Sarasquete ME, Garcia-Sanz R, Marin L, et al: Bisphosphonate- Maxillofac Surg 67:96, 2009 (suppl 1)
related osteonecrosis of the jaw is associated with polymor- 72. Lee CY, David T, Nishime M: Use of platelet-rich plasma in the
phisms of the cytochrome P450 CYP2C8 in multiple myeloma: management of oral bisphosphonate-associated osteonecrosis
A genome-wide single nucleotide polymorphism analysis. of the jaw: A report of two cases. J Oral Implantol 33:371, 2007
Blood 112:2709, 2008 73. National Institutes of Health: Funding opportunities and notices
61. Dimopoulos MA, Kastritis E, Bamia C, et al: Reduction of search results. Available at: http://grants.nih.gov/grants/guide/
osteonecrosis of the jaw (ONJ) after implementation of preven- search_results.htm?text_curr⫽osteonecrosis&scope⫽pa-rfa&year⫽
tive measures in patients with multiple myeloma treated with active&sort⫽&Search.x⫽10&Search.y⫽8. Accessed November 19,
zoledronic acid. Ann Oncol 20:117, 2009 2008